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The suprachiasmatic nuclei in the hypothalamus, one of the most important physiological determinants of alertness and performance,
drive a circadian pacemaker in mammals, with an intrinsic period averaging 24h. Light is the primary stimulus to the disruption and
resetting of this pacemaker, which is expressed in changing melatonin rhythms. Melatonin production in humans decreases when
people are exposed to light at night. Since melatonin shows potential oncostatic action in a variety of tumours, it is possible that
lowered serum melatonin levels caused by exposure to light at night enhance the general tumour development. Cancer is the second
leading cause of death in industrialised countries like the United States, where a significant proportion of workers engage in shift work,
making a hypothesised relation between light exposure at night and cancer risk relevant. Observational studies support an association
between night work and cancer risk. We hypothesise that the potential primary culprit for this observed association is the lack of
melatonin, a cancer-protective agent whose production is severely diminished in people exposed to light at night.
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Light and melatonin
Light at night is an environmental exposure that has become
integral to our lives. Before 1879, when the light-bulb was invented,
humans were exposed to only insignificant amounts of low-
intensity light at night from sources such as candles and petroleum
lamps. Later on, paralleled by growing industrialisation, a need for
longer days emerged, with electric light making it possible to push
multifaceted working schedules further and further into the night.
Today, exposure to light at night, both in the form of occupational
exposure during night work and as a personal choice and lifestyle,
is experienced by numerous night-active members of our societies.
We, however, do not appear to be well adapted to bright nights:
shift workers, for instance, reportedly suffer from a variety of
health problems (Vener et al, 1989; Costa, 1997; Boggild and
Knutsson, 1999). Previously, humans tended to conduct their daily
activities according to the sun’s cycle: rising at sunrise and going
to bed at sunset. Such sleep rhythms appear not only to be more
natural, but also to be essential for a variety of physiologic
functions in humans, such as body temperature, excretion, and the
production of hormones (Weitzman et al, 1981; Czeisler and
Klerman, 1999). Melatonin, for example, follows a very distinct
pattern of production, which is very closely linked to the
individual’s circadian rhythm, following light exposure: during
the day, almost no melatonin is produced, whereas during the
night, when it is dark, almost all melatonin is produced (Snyder
et al, 1967). Environmental lighting powerfully alters physiologic
release of melatonin, which typically peaks in the middle of the
night (Zeitzer et al, 2000): a profound melatonin reduction was
observed in humans after 2 weeks of intermittent nightly exposure
to light (Zeitzer et al, 2000; Graham and Cook, 2001). While levels
may recover during the periods of sleep, they will not recover to
their maximal amount unless habits are kept constant, because any
disruption of a natural circadian rhythm will diminish the ability
to recover from that suppression.
Link between light at night and breast cancer risk through
the oestrogen pathway
Past studies suggested that the excess breast cancer mortality seen
in urban areas as well as the North East as compared to the South
of the US could be due to differences in exposure to sunlight
(Garland et al, 1990), perhaps mediated through the vitamin D
pathway. However, based on a large body of experimental work in
the 1960s and 70s, evidence grew that visible light, including
artificial light, can acutely suppress melatonin. Thus, novel
hypotheses were generated, proposing that the diminished
function of the pineal gland might promote the development of
breast cancer in humans. One of the initial theories supporting that
a diminished function of the pineal gland might promote the
development of cancer hypothesised that melatonin suppression
may lead to an increase in levels of reproductive hormones,
particularly oestradiol, thereby increasing the growth and pro-
liferation of hormone-sensitive cells in the breast (Cohen et al,
1978; Stevens, 1987).
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that women in occupations that expose them to light at night do
experience a higher risk of breast cancer, and that blind women,
who do not have the ability to experience lower melatonin levels
because of their supposed lack of receptivity to light, have a lower
incidence of breast cancer (Schernhammer and Hankinson, 2003).
Studies fairly consistently report meaningful increases in breast
cancer risk among postmenopausal women exposed to shift work
(Pukkala et al, 1995; Tynes et al, 1996; Davis et al, 2001; Hansen,
2001; Rafnsson et al, 2001; Schernhammer et al, 2001). Two
retrospective studies of flight attendants with occupational
exposure to light at night linked the employment time to an
increased risk of breast cancer (Pukkala et al, 1995; Rafnsson et al,
2001). Two nationwide record linkage studies (Tynes et al, 1996;
Hansen, 2001) and a retrospective case–control study (Davis et al,
2001) associated night work with an approximately 50% higher
risk of breast cancer (Tynes et al, 1996; Hansen, 2001). Finally, the
Nurses’ Health Study, the only prospective study published that
evaluated the association, observed a positive association of
extended periods of rotating night work and breast cancer risk
(more than 30 years of rotating night work: RR¼1.36; 95%
CI¼1.04–1.78) (Schernhammer et al, 2001). In this study, night
work was defined as the total number of years during which the
nurses had worked rotating night shifts with at least three nights
per month, in addition to days and evenings in that month. During
10 years of follow-up, 2441 incident cases of breast cancer were
documented among 78562 women. A positive association between
the number of years a woman had worked on rotating night shifts
and breast cancer risk was observed (test for trend, P¼0.02).
Among postmenopausal women, the relative risk for breast cancer,
controlling for all the major risk factors for breast cancer, was
moderately increased after 1–14 and 15–29 years of rotating night
shift work, and was further increased (RR 1.36; 95% CI 1.04–1.78)
for those nurses who worked the night shift for 30 or more years,
with similar risks for premenopausal women (RR 1.34; 95% CI
0.77–2.33). Thus, in sum, observational studies seem to support
the hypothesis that night work increases the risk for breast cancer.
This association may be mediated, at least in part, by the oestrogen
pathway.
Light at night and other cancers
Only few previous observational studies have addressed the
relationship between shift work and cancers, other than breast
cancer. Early suggestions for an increased cancer risk related to
shift work arose from two mortality studies that were conducted
among male shift workers to assess the influence of shift work
upon total and cause-specific mortality, with suggestions for an
increased cancer mortality related to shift work. Tynes et al report
an increased risk of colon (SIR 1.3; 95% CI 0.6–2.6) and rectum
cancer (SIR 1.8; 95% CI 0.7–3.9) in their cohort of female radio
and telegraph workers. Rafnsson and colleagues do not report the
risks for colorectal cancer among the female Icelandic flight
attendants, but describe an elevated risk for tumours of the
lymphatic system.
CANCER-PROTECTIVE EFFECTS OF MELATONIN
In recent years, an overwhelming amount of research has been
devoted to exploring the cancer-protective properties of the
hormone melatonin. Today, many of the oncostatic properties of
melatonin have been fairly well described (Vijayalaxmi et al, 2002),
and evidence from experimental studies strongly suggests a link
between melatonin and tumour suppression (Schernhammer and
Hankinson, 2003). In vitro studies, although not entirely consistent
(Panzer et al, 1998), give support to a reduction in the growth of
malignant cells of the breast (Hill and Blask, 1988; Cos et al, 1996,
1998, 2002; Mediavilla et al, 1999) and other tumour sites (Sze et al,
1993; Ying et al, 1993; Petranka et al, 1999; Shiu et al, 1999; Kanishi
et al, 2000) by both pharmacological and physiologic doses of
melatonin. In rodent models, pinealectomy boosts tumour growth
(Tamarkin et al, 1981), whereas exogenous melatonin administra-
tion exerts anti-initiating (Musatov et al, 1999) and oncostatic
activity (Anisimov et al, 1997, 1999; Cini et al, 1998; Mocchegiani
et al, 1999) in various chemically induced cancers. The most
prominent mechanisms proposed to explain the oncostatic action
of melatonin include its antimitotic and antioxidant activity
(Brzezinski, 1997), and its potential modulation of cell-cycle
length through control of the p53–p21 pathway (Mediavilla et al,
1999). Melatonin is believed to have antimitotic activity by its
direct effect on hormone-dependent proliferation through inter-
action with nuclear receptors. Another explanation is that
melatonin increases the expression of the tumour-suppressor gene
p53. Cells lacking p53 have been shown to be genetically unstable
and thus more prone to tumours.
In vitro studies do support not only an effect of melatonin on
breast cancer (Hill and Blask, 1988; Cos et al, 1996, 1998, 2002;
Mediavilla et al, 1999), but also on other tumours. In fact, to date,
melatonin has been shown to be oncostatic for a variety of tumour
cells in experimental carcinogenesis (Sze et al, 1993; Ying et al,
1993; Petranka et al, 1999; Shiu et al, 1999; Kanishi et al, 2000).
Reports show that melatonin exhibits a growth-inhibitory effect on
endometrial (Kanishi et al, 2000) and ovarian carcinoma cell lines
(Petranka et al, 1999), Lewis lung carcinoma (Mocchegiani et al,
1999), prostate tumour cells (Laufer et al, 1999), and intestinal
tumours (Anisimov et al, 1997, 2000a,b), for example. Further-
more, today, several clinical trials confirm the potential of
melatonin, either alone or in combination with standard therapy
regimens, to generate a favourable response in the treatment of
human cancers (Vijayalaxmi et al, 2002).
UPDATING THE MELATONIN HYPOTHESIS
Given the evidence from experimental studies supporting the
general oncostatic property of melatonin, we therefore speculate
that exposure to light at night not only has an impact on breast
cancer risk, but also may increase the risk of other cancers,
primarily through the melatonin pathway. This has been posed
previously (Kerenyi et al, 1990) without much further attention
from the scientific community, but most recent evidence from
observational studies supports such a link. The Nurses’ Health
Study Cohort was used to explore the association between night
work and colorectal cancer; 602 women were diagnosed with
incident colorectal cancer during the 10 years of follow-up. In
these analyses, women who worked 15 or more years on rotating
night shifts were at a higher risk of colorectal cancer than were
women who never worked rotating night shifts. The relative risks
after adjustment for age, smoking, physical activity, and other
colorectal cancer risk factors were 1.00 (0.84–1.19) for 1–14 years
on rotating night shifts and 1.35 (1.03–1.77) for 15 or more years
on rotating night shifts (test for trend, P¼0.04).
On the basis of the observed effect of night work on colorectal
cancer, which, contrary to breast cancer cannot be fully explained
by variations in circulating oestrogen levels, taken together with
consistent evidence from experimental studies, we believe that the
effects of light exposure at night on cancer risk may be explained,
at least in part, by the direct oncostatic mechanisms of melatonin.
We propose that an increase in light exposure during the
night decreases the amount of time available for melatonin
production, which reduces the possible nonspecific oncostatic
effect of the pineal gland, thus increasing the risk not only of
breast cancer but also of other cancers. Although other aetiologic
mechanisms, such as the loss of normal diurnal variation in
cortisol (Spiegel and Sephton, 2002), may be involved in the
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may be the primary culprit for this association. Future research
should therefore evaluate the relationship of light exposure to the
risk of not only breast but also other cancers, including cancer
risks in men. There is also a need for research that addresses
individual susceptibility and the question whether individuals with
lower melatonin levels choose to do night work more often than do
those with higher melatonin levels. First and foremost, however,
associations between melatonin levels and cancer risk in humans
need to be evaluated.
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